TScan Therapeutics (TCRX) Change in Cash (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Change in Cash of -$24.3 million for Q1 2026, up 0.94% year-over-year from -$24.1 million in Q1 2025, and down 42.39% quarter-over-quarter from -$17.1 million in Q4 2025.
TScan Therapeutics (TCRX) Change in Cash (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Change in Cash for 7 consecutive years, with -$24.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash rose 0.94% year-over-year to -$24.3 million; the TTM figure through Mar 2026 stood at -$26.1 million (down 291.62% YoY), while the FY2025 annual figure was -$26.3 million, down 157.98% from the prior year.
- Change in Cash slipped to -$24.3 million in Q1 2026 per TCRX's latest filing, from -$17.1 million in the prior quarter.
- Across five years, Change in Cash topped out at $113.2 million in Q2 2023 and bottomed at -$109.0 million in Q3 2024.
- Historically, Change in Cash has averaged -$2.0 million across 5 years, with a median of -$17.1 million in 2025.
- On a YoY basis, Change in Cash climbed as much as 843.54% in 2023 and fell as far as 558.42% in 2023.
- TScan Therapeutics' Change in Cash stood at -$17.3 million in 2022, then declined by 26.36% to -$21.8 million in 2023, then soared by 308.72% to $45.6 million in 2024, then slumped by 137.52% to -$17.1 million in 2025, then sank by 42.39% to -$24.3 million in 2026.
- Business Quant data shows TCRX's Change in Cash at -$24.3 million in Q1 2026, -$17.1 million in Q4 2025, and $112000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | -27.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.90 Mn |
| Mar 31, 2026 | -24.35 Mn |
| Dec 31, 2025 | -17.10 Mn |
| Sep 30, 2025 | 112,000.00 |
| Jun 30, 2025 | 15.29 Mn |
| Mar 31, 2025 | -24.58 Mn |
| Dec 31, 2024 | 45.57 Mn |
| Sep 30, 2024 | -109.04 Mn |
| Jun 30, 2024 | 101.65 Mn |
| Mar 31, 2024 | 7.15 Mn |
| Dec 31, 2023 | -21.83 Mn |
| Sep 30, 2023 | -53.65 Mn |
| Jun 30, 2023 | 113.23 Mn |
| Mar 31, 2023 | -24.43 Mn |
| Dec 31, 2022 | -17.28 Mn |
| Sep 30, 2022 | 11.70 Mn |
| Jun 30, 2022 | -15.23 Mn |
| Mar 31, 2022 | -20.57 Mn |
| Dec 31, 2021 | -16.47 Mn |
| Sep 30, 2021 | 76.12 Mn |